The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects

Archives of Drug Information

Volumn 3, Issue 4, 2010, Pages 55-62

  Han, Tae H ^a,b   Blanchard, Rebecca L ^a   Palcza, John ^a   Martucci, Ashley ^a   Miller Stein, Cynthia M ^a   Gutierrez, Maria ^c   Panebianco, Deborah ^a   Rippley, Ronda K ^a   Lines, Christopher ^a   Murphy, M Gail ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SEATTLE GENETICS INC   (United States)

^c Comprehensive Phase One ^*  (United States)

Author keywords

Dose Proportionality; Migraine; Pharmacokinetics; Telcagepant

Indexed keywords

TELCAGEPANT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONSTIPATION; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; INFUSION PAIN; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION;

EID: 78851469227     PISSN: None     EISSN: 17535174     Source Type: Journal    
DOI: 10.1111/j.1753-5174.2010.00031.x     Document Type: Article

References (13)

1. Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, etal. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210.
2. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 1999;15:813-8.
3. Durham PL. Inhibition of calcitonin gene-related peptide function: A promising strategy for treating migraine. Headache 2008;48:1269-75.
4. Tepper SJ, Stillman MJ. Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine. Headache 2008;48:1259-68.
5. Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, etal. Triptan Cardiovascular Safety Expert Panel. Consensus statement: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004;44:414-25.
6. Paone DV, Shaw AW, Nguyen DN, Burgey CS, Deng JZ, Kane SA, etal. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: Discovery of N-[(3R, 6S)-6-(2, 3-difluorophenyl)-2-oxo-1- (2, 2, 2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2, 3-dihydro-1H-imidazo[4, 5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). J Med Chem 2007;50:5564-7.
7. Salvatore CA, Hershey JC, Corcoran HA, Fay JF, Johnston VK, Moore EL, etal. Pharmacological characterization of MK-0974 [N-[(3R, 6S)-6-(2, 3-difluorophenyl)-2-oxo-1-(2, 2, 2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2, 3-dihydro-1H-imidazo[4, 5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008;324:416-21.
8. Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, etal. MK-0974 Protocol 004 study group. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008;70:1304-12.
9. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, etal. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:2115-23.
10. Connor KM, Shapiro RE, Diener H-C, Lucas S, Kost J, Fan X, etal. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009;73:970-7.
11. Roller S, Cui D, Laspina C, Miller-Stein C, Rowe J, Wong B, etal. Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences. Xenobiotica 2009;39:33-45.
12. Han TH, Blanchard RL, Palcza J, McCrea JB, Laethem T, Willson KJ, etal. Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J Clin Pharmacol 2010;50:1367-76.
13. Xu Y, Willson KW, Anderson MDG, Miller-Stein CM, Woolf EJ. Elimination of diastereomer interference to determine Telcagepant (MK-0974) in human plasma using on-line turbulent-flow technology and off-line solid-phase extraction coupled with liquid chromatography/tandem mass spectrometry. J Chromatogr B 2009;877:1634-42.